FDG PET/CT的TLR对切缘阴性IB-IIA期非小细胞肺癌的预后价值
该回顾性研究纳入112例切缘阴性IB-IIA期NSCLC患者,评估FDG PET/CT的肿瘤-肝脏SUV比值(TLR)的预后价值。多因素分析显示TLR与更短的无病生存期(HR=1.263,p=0.008)和总生存期(HR=1.422,p<0.001)独立相关,提示TLR可作为考虑辅助治疗的预后风险因素。
要点
- TLR是IB-IIA期NSCLC切缘阴性患者独立不良预后因素
- 高TLR患者无病生存期和总生存期均显著缩短
- TLR可能辅助筛选需要术后辅助治疗的高危患者
核心结论
- FDG PET/CT的TLR是切缘阴性IB-IIA期NSCLC患者复发和生存的独立预后因素。
- PET参数可作为考虑辅助治疗决策的风险因素,高TLR患者术后应考虑辅助治疗。
研究设计与样本
- 回顾性研究,连续纳入112例初诊分期为IB和IIA期NSCLC并接受FDG PET/CT检查的患者。
- 获取原发肿瘤SUVmax和肝脏平均SUV,计算肿瘤-肝脏SUV比值(TLR)。
- 参考标准为病理及临床随访,采用Cox回归和Kaplan-Meier法进行统计分析。
诊断标准与关键数值
- 多因素分析中,TLR与更短DFS相关(HR=1.263,p=0.008),分化程度与更短DFS相关(HR=3.087,p=0.012)。
- 多因素分析中,TLR与更短OS相关(HR=1.422,p<0.001)。
- 单因素分析中,病理、低分化和TLR与更短DFS和OS相关。
临床应用与阅片要点
- 在日常阅片中可计算TLR(原发肿瘤SUVmax/肝脏平均SUV),作为预后风险分层参考。
- 对切缘阴性IB-IIA期NSCLC患者,高TLR提示复发和死亡风险较高,可提醒临床考虑辅助治疗。
局限性
- 回顾性研究设计。
- 单中心研究,样本量有限(112例)。
- TLR用于辅助治疗决策仍需额外验证研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the prognostic value of TLR from PET/CT in patients with resection margin-negative stage IB and IIA non-small cell lung cancer (NSCLC) and compare high-risk factors necessitating adjuvant treatment (AT).
METHODS: Consecutive FDG PET/CT scans performed for the initial staging of NSCLC stage IB and IIA were retrospectively reviewed. The maximum standardized uptake value (SUVmax) of the primary tumor and mean SUV of the liver were acquired. The tumor-to-liver SUV ratio (TLR) was also calculated. Charts were reviewed for basic patient characteristics and high-risk factors for considering AT (poor differentiation, visceral pleura invasion, vascular invasion, tumors > 4 cm, and wedge resection). Statistical analysis was performed using Cox regression analysis and the Kaplan-Meier method.
RESULTS: Of the 112 patients included, 15 (13.4%) died, with a median overall survival (OS) of 43.8 months. Twenty-two patients (19.6%) exhibited recurrence, with median disease-free survival (DFS) of 36.0 months. In univariable analysis, pathology, poor differentiation, and TLR were associated with shorter DFS and OS. In multivariable analysis, TLR (hazard ratio [HR] = 1.263, p = 0.008) and differentiation (HR = 3.087, p = 0.012) were associated with shorter DFS. Also, TLR (HR = 1.422, p < 0.001) was associated with shorter OS.
CONCLUSION: TLR from FDG PET/CT was an independent prognostic factor for recurrence and survival. PET parameters constitute risk factors for consideration in the decision-making for AT in margin-negative stage IB and IIA NSCLC.
CLINICAL RELEVANCE STATEMENT: In this study, TLR from FDG PET/CT was an independent prognostic factor in stage IB-IIA non-small cell cancer patients. Although additional validation studies are warranted, TLR has the potential to be used to determine the need for adjuvant therapy.
KEY POINTS: • High TLR is an independent poor prognostic factor in stage IB-IIA NSCLC. • Adjuvant treatment should be considered in patients with high TLR following complete tumor resection.
引用
- Park, Boo, Park, et al. Prognostic value of TLR from FDG PET/CT in patients with margin-negative stage IB and IIA non-small cell lung cancer. Eur Radiol. 2023. PMID: 37060445. doi:10.1007/s00330-023-09641-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。